Comparison High-Density Silicone Oils in Retinal Detachment
Unknown status
Asociación para Evitar la Ceguera en México
Phase 2/Phase 3
2006-08-01
The purpose of the study is to compare the safety, intraocular adverse effects and the
anatomic and functional outcome with two endotamponade silicone oil after a 3-month in
complex inferior retinal re-detachments.
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Completed
Novaliq GmbH
Phase 2
2018-01-03
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane
(NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye
Disease (DED).
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
Completed
Bausch & Lomb Incorporated
Phase 3
2020-07-20
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution
in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye
Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
Completed
Novaliq GmbH
Phase 3
2020-07-20
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution
in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye
Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
Recruiting
Bausch & Lomb Incorporated
Phase 3
2020-09-24
The objectives of this trial are to evaluate the safety and tolerability of
perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry
Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction).
Further objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during
long-term use in subjects with DED associated with MGD.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
